Stifel Financial Corp Aldeyra Therapeutics, Inc. Transaction History

Stifel Financial Corp

$93.2 Billion
Q3 2024

A detailed history of Stifel Financial Corp transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Stifel Financial Corp holds 16,108 shares of ALDX stock, worth $88,271. This represents 0.0% of its overall portfolio holdings.

Number of Shares

16,108

Previous 15,517 3.81%

Holding current value

$88,271

Previous $51,000 68.63%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.19 - $6.32 $1,885 - $3,735	591 Added 3.81%	16,108 $86,000
Q2 2024 Aug 13, 2024	BUY	$3.25 - $4.72 $50,430 - $73,240	15,517 New	15,517 $51,000
Q4 2023 Feb 12, 2024	SELL	$1.47 - $6.06 $18,076 - $74,519	-12,297 Reduced 48.56%	13,026 $45,000
Q3 2023 Nov 13, 2023	SELL	$6.11 - $8.16 $82,448 - $110,111	-13,494 Reduced 34.76%	25,323 $169,000
Q2 2023 Aug 14, 2023	BUY	$7.11 - $11.89 $79,916 - $133,643	11,240 Added 40.76%	38,817 $325,000
Q1 2023 May 12, 2023	BUY	$5.77 - $9.93 $72,984 - $125,604	12,649 Added 84.73%	27,577 $273,000
Q4 2022 Feb 13, 2023	SELL	$5.08 - $7.09 $5,080 - $7,090	-1,000 Reduced 6.28%	14,928 $103,000
Q3 2022 Nov 14, 2022	SELL	$3.8 - $7.74 $13,433 - $27,360	-3,535 Reduced 18.16%	15,928 $85,000
Q2 2022 Aug 15, 2022	SELL	$2.43 - $4.85 $12,827 - $25,603	-5,279 Reduced 21.34%	19,463 $78,000
Q1 2022 May 13, 2022	SELL	$3.25 - $5.17 $31,963 - $50,846	-9,835 Reduced 28.44%	24,742 $110,000
Q4 2021 Feb 14, 2022	SELL	$3.5 - $9.63 $119,738 - $329,451	-34,211 Reduced 49.73%	34,577 $138,000
Q3 2021 Nov 15, 2021	BUY	$7.94 - $11.31 $103,148 - $146,928	12,991 Added 23.28%	68,788 $604,000
Q2 2021 Aug 13, 2021	SELL	$10.44 - $14.85 $108,513 - $154,350	-10,394 Reduced 15.7%	55,797 $632,000
Q1 2021 May 14, 2021	SELL	$6.53 - $14.42 $163,315 - $360,644	-25,010 Reduced 27.42%	66,191 $786,000
Q4 2020 Feb 12, 2021	SELL	$6.31 - $8.13 $30,477 - $39,267	-4,830 Reduced 5.03%	91,201 $626,000
Q3 2020 Nov 16, 2020	SELL	$4.0 - $7.53 $73,368 - $138,115	-18,342 Reduced 16.04%	96,031 $712,000
Q2 2020 Aug 14, 2020	BUY	$1.97 - $5.05 $88,971 - $228,073	45,163 Added 65.26%	114,373 $477,000
Q1 2020 May 14, 2020	SELL	$1.62 - $6.4 $16,404 - $64,806	-10,126 Reduced 12.76%	69,210 $168,000
Q4 2019 Feb 13, 2020	BUY	$4.73 - $7.98 $251,806 - $424,823	53,236 Added 203.97%	79,336 $461,000
Q3 2019 Nov 13, 2019	SELL	$4.41 - $6.12 $112,230 - $155,747	-25,449 Reduced 49.37%	26,100 $137,000
Q2 2019 Aug 14, 2019	BUY	$6.0 - $9.0 $210,180 - $315,270	35,030 Added 212.06%	51,549 $310,000
Q1 2019 May 14, 2019	BUY	$7.14 - $9.85 $41,162 - $56,785	5,765 Added 53.61%	16,519 $152,000
Q4 2018 Feb 13, 2019	SELL	$7.26 - $13.29 $23,232 - $42,528	-3,200 Reduced 22.93%	10,754 $88,000
Q3 2018 Nov 13, 2018	BUY	$6.8 - $14.35 $23,371 - $49,320	3,437 Added 32.68%	13,954 $193,000
Q2 2018 Aug 14, 2018	BUY	$6.95 - $9.18 $1,042 - $1,377	150 Added 1.45%	10,517 $85,000
Q1 2018 May 11, 2018	BUY	$6.55 - $8.9 $67,903 - $92,266	10,367 New	10,367 $79,000

Others Institutions Holding ALDX

# of Institutions

117

Shares Held

36.2M

Call Options Held

196K

Put Options Held

142K

View Full List

About Aldeyra Therapeutics, Inc.

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $320M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

More about ALDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Stifel Financial Corp with notifications on news.

Account

Stifel Financial Corp Aldeyra Therapeutics, Inc. Transaction History